news 2020
« BACK
Chemistry - Pharmacology - 12.11.2020
Health - Pharmacology - 11.11.2020
Pharmacology - Health - 10.11.2020
Health - Pharmacology - 10.11.2020
Pharmacology - Life Sciences - 04.11.2020
Health - Pharmacology - 04.11.2020
Pharmacology - Health - 03.11.2020
Health - Pharmacology - 28.10.2020
Pharmacology - Health - 27.10.2020
Pharmacology - Health - 27.10.2020
Pharmacology - Health - 23.10.2020
Pharmacology - Life Sciences - 22.10.2020
Health - Pharmacology - 21.10.2020
Health - Pharmacology - 21.10.2020
Health - Pharmacology - 19.10.2020
Health - Pharmacology - 19.10.2020
Health - Pharmacology - 19.10.2020
Health - Pharmacology - 15.10.2020
Pharmacology - Life Sciences - 12.10.2020
Health - Pharmacology - 12.10.2020
Pharmacology
Results 21 - 40 of 187.
Interactive virtual reality emerges as a new tool for drug design against COVID-19
Bristol scientists have demonstrated a new virtual reality [VR] technique which should help in developing drugs against the SARS-CoV-2 virus - and enable researchers to share models and collaborate in new ways. The innovative tool, created by University of Bristol researchers, and published in the Journal of Chemical Information and Modeling, will help scientists around the world identify anti-viral drug leads more rapidly.
Bristol scientists have demonstrated a new virtual reality [VR] technique which should help in developing drugs against the SARS-CoV-2 virus - and enable researchers to share models and collaborate in new ways. The innovative tool, created by University of Bristol researchers, and published in the Journal of Chemical Information and Modeling, will help scientists around the world identify anti-viral drug leads more rapidly.
Insights into ’significant’ avoidable harm in primary care
A national study in England has revealed the extent of incidents of significant avoidable harm in primary care. Thirteen GPs reviewed case notes of more than 90,000 patients in three regions across England over a 12-month period as part of the study. They found the main causes of avoidable harm were diagnostic error (more than 60%), medication incidents (more than 25%) and delayed referrals (nearly 11%), and that 80% of incidents could have been identified sooner or prevented if action had been taken.
A national study in England has revealed the extent of incidents of significant avoidable harm in primary care. Thirteen GPs reviewed case notes of more than 90,000 patients in three regions across England over a 12-month period as part of the study. They found the main causes of avoidable harm were diagnostic error (more than 60%), medication incidents (more than 25%) and delayed referrals (nearly 11%), and that 80% of incidents could have been identified sooner or prevented if action had been taken.
Next-generation immunotherapy entering early phase clinical trials
Scientists at UCL have invented a new experimental drug that aims to harness the full power of the immune system, launching a two-pronged response against cancer. The pioneering study in mice has been co-funded by Cancer Research UK. The innovative immunotherapy drug, developed by researchers at UCL Cancer Institute, targets suppressive 'regulatory' immune cells inside a tumour.
Scientists at UCL have invented a new experimental drug that aims to harness the full power of the immune system, launching a two-pronged response against cancer. The pioneering study in mice has been co-funded by Cancer Research UK. The innovative immunotherapy drug, developed by researchers at UCL Cancer Institute, targets suppressive 'regulatory' immune cells inside a tumour.
Newer medicine to prevent gout attacks is as safe as older treatment
A major new study examining the relative safety of medicines for the treatment of gout will be presented at the American College of Rheumatology Convergence conference and will be published in The Lancet. The FAST Study finds no increased risk of cardiovascular events with febuxostat as compared with allopurinol.
A major new study examining the relative safety of medicines for the treatment of gout will be presented at the American College of Rheumatology Convergence conference and will be published in The Lancet. The FAST Study finds no increased risk of cardiovascular events with febuxostat as compared with allopurinol.
Scientists uncover new layer of complexity in how our bodies respond to drug treatments
Scientists from the University of Glasgow have played an important role in understanding why some patients respond better to drug treatments than others. The study - and involving the University of Glasgow and a number of international partners - uncovers a new layer of complexity in how the body responds to medical treatments by using the power of data analysis on GPCRs.
Scientists from the University of Glasgow have played an important role in understanding why some patients respond better to drug treatments than others. The study - and involving the University of Glasgow and a number of international partners - uncovers a new layer of complexity in how the body responds to medical treatments by using the power of data analysis on GPCRs.
Funding for salmon drugs may help lower cost of treating deadly human diseases
The University of Glasgow has received funding to repurpose drugs that are currently used to treat some parasitic diseases in humans - Sleeping Sickness, Chagas Disease and Leishmaniasis - to manage amoebic gill disease in Atlantic salmon. Researchers hope that opening new markets for these drugs in the developed world will also help to drive down their costs in the developing world, where unaffordable healthcare can lead to many unnecessary deaths.
The University of Glasgow has received funding to repurpose drugs that are currently used to treat some parasitic diseases in humans - Sleeping Sickness, Chagas Disease and Leishmaniasis - to manage amoebic gill disease in Atlantic salmon. Researchers hope that opening new markets for these drugs in the developed world will also help to drive down their costs in the developing world, where unaffordable healthcare can lead to many unnecessary deaths.
New study into a rare type of cancer in abdomen lining shows possible immunotherapy treatment
A new study from the University of Birmingham has found that 50% of patients with a rare type of cancer that has spread into the lining of their abdomen may be suitable for immunotherapy treatment. Unfortunately for around 1% of bowel cancer patients, their cancer spreads to the lining of their abdomen (peritoneal cavity) - known as colorectal peritoneal metastasis (CPM).
A new study from the University of Birmingham has found that 50% of patients with a rare type of cancer that has spread into the lining of their abdomen may be suitable for immunotherapy treatment. Unfortunately for around 1% of bowel cancer patients, their cancer spreads to the lining of their abdomen (peritoneal cavity) - known as colorectal peritoneal metastasis (CPM).
Antiviral drugs trialled in the early stages of COVID-19
Two antiviral drugs are being given to COVID-19 positive adults to establish if they stop the virus replicating, as part of a trial led by UCL scientists. The FLARE trial aims to see if favipiravir and lopinavir/ritonavir, alone or in combination, can inhibit viral replication in early infection - within the first few days of illness.
Two antiviral drugs are being given to COVID-19 positive adults to establish if they stop the virus replicating, as part of a trial led by UCL scientists. The FLARE trial aims to see if favipiravir and lopinavir/ritonavir, alone or in combination, can inhibit viral replication in early infection - within the first few days of illness.
Common diabetes drugs may help prevent Parkinson’s
Elevated risk of Parkinson's disease among people with type 2 diabetes appears to be reduced by some medications used to treat their diabetes, finds a new study led by UCL researchers. The researchers are testing one of the drugs, called exenatide, as a potential Parkinson's treatment in an upcoming clinical trial, and the new findings, published in Brain , lend support to repurposing diabetes medications for people with Parkinson's.
Elevated risk of Parkinson's disease among people with type 2 diabetes appears to be reduced by some medications used to treat their diabetes, finds a new study led by UCL researchers. The researchers are testing one of the drugs, called exenatide, as a potential Parkinson's treatment in an upcoming clinical trial, and the new findings, published in Brain , lend support to repurposing diabetes medications for people with Parkinson's.
High blood pressure and its drug treatment unlikely to increase entry of COVID-19 virus into cells
Fears that people with high blood pressure are more at risk from severe Covid-19 because it is easier for the virus to enter their cells and tissues have been laid to rest, thanks to research by an international team of scientists The team led by University of Manchester, and including University of Glasgow researchers, also show that speculation over some blood pressure lowering medications that they increase the risk of Covid-19 infection, is likely to be wrong.
Fears that people with high blood pressure are more at risk from severe Covid-19 because it is easier for the virus to enter their cells and tissues have been laid to rest, thanks to research by an international team of scientists The team led by University of Manchester, and including University of Glasgow researchers, also show that speculation over some blood pressure lowering medications that they increase the risk of Covid-19 infection, is likely to be wrong.
Cardiff University-led study into antibiotic use wins research paper of the year
A study into antibiotic use led by Cardiff University and in collaboration with the University of Oxford and King's College London has won research paper of the year. The study, by researchers from Cardiff University's School of Medicine and Centre for Trials Research, found a simple finger-prick blood test could help to prevent unnecessary prescription of antibiotics in patients with chronic obstructive pulmonary disease (COPD).
A study into antibiotic use led by Cardiff University and in collaboration with the University of Oxford and King's College London has won research paper of the year. The study, by researchers from Cardiff University's School of Medicine and Centre for Trials Research, found a simple finger-prick blood test could help to prevent unnecessary prescription of antibiotics in patients with chronic obstructive pulmonary disease (COPD).
Oxford COVID-19 vaccine follows its programmed genetic instructions, independent analysis finds
The AstraZeneca Oxford COVID-19 vaccine (ChAdOx1 nCoV-19 and also known as AZD1222) now undergoing Phase III clinical trials, has already undergone rigorous testing to ensure the highest standards of quality and safety. Now a team at Bristol University has used recently developed techniques to further validate that the vaccine accurately follows the genetic instructions programmed into it by the Oxford team.
The AstraZeneca Oxford COVID-19 vaccine (ChAdOx1 nCoV-19 and also known as AZD1222) now undergoing Phase III clinical trials, has already undergone rigorous testing to ensure the highest standards of quality and safety. Now a team at Bristol University has used recently developed techniques to further validate that the vaccine accurately follows the genetic instructions programmed into it by the Oxford team.
Palliative care needed across China for everyone who needs it - study
Palliative care should extend across China and pay more attention to managing non-malignant disease - integrated within the country's healthcare system and available to everyone who needs it, according to a new study. Researchers have found that, with rapidly aging populations, there is an increasing need for palliative care across Greater China - Hong Kong, Macao, mainland China and Taiwan - to help improve quality of life, as well as reducing pain, anxiety and depression.
Palliative care should extend across China and pay more attention to managing non-malignant disease - integrated within the country's healthcare system and available to everyone who needs it, according to a new study. Researchers have found that, with rapidly aging populations, there is an increasing need for palliative care across Greater China - Hong Kong, Macao, mainland China and Taiwan - to help improve quality of life, as well as reducing pain, anxiety and depression.
Key research role in COVID-19 Human Challenge Study
Scientists across UCL will play a key role in the world's first human challenge study of the SARS-CoV-2 virus, providing new insight into the body's immune response and finding out which vaccines are likely to work. The COVID-19 Human Challenge Programme, funded through the UK Government's Vaccines Taskforce, is being run in partnership with Imperial College London, the Department for Business, Energy & Industrial Strategy (BEIS), hVIVO, a leading clinical company with expertise in viral human challenge models, and the Royal Free London NHS Foundation Trust.
Scientists across UCL will play a key role in the world's first human challenge study of the SARS-CoV-2 virus, providing new insight into the body's immune response and finding out which vaccines are likely to work. The COVID-19 Human Challenge Programme, funded through the UK Government's Vaccines Taskforce, is being run in partnership with Imperial College London, the Department for Business, Energy & Industrial Strategy (BEIS), hVIVO, a leading clinical company with expertise in viral human challenge models, and the Royal Free London NHS Foundation Trust.
Medium-term impact of COVID-19 revealed in new study
Initial findings from a study looking at the longer-term impact of COVID-19 has found that a large proportion COVID-19 patients discharged from hospital were still experiencing symptoms of breathlessness, fatigue, anxiety and depression two to three months after contracting the virus. The University of Oxford scientists carrying out the C-MORE study have also detected abnormalities on MRI in multiple organs and believe that persistent or chronic inflammation may be an underlying factor for these changes among COVID-19 survivors.
Initial findings from a study looking at the longer-term impact of COVID-19 has found that a large proportion COVID-19 patients discharged from hospital were still experiencing symptoms of breathlessness, fatigue, anxiety and depression two to three months after contracting the virus. The University of Oxford scientists carrying out the C-MORE study have also detected abnormalities on MRI in multiple organs and believe that persistent or chronic inflammation may be an underlying factor for these changes among COVID-19 survivors.
Risk predictor could eliminate TB in countries with low transmission
A new online tool which could help eliminate tuberculosis in countries with low transmission rates such as the UK, by identifying who is at highest risk of developing TB, has been developed by UCL researchers. The research, published today , is the largest study of its kind and pooled data from 18 previous studies and 20 countries including the UK and from across Western Europe, North America and Australia.
A new online tool which could help eliminate tuberculosis in countries with low transmission rates such as the UK, by identifying who is at highest risk of developing TB, has been developed by UCL researchers. The research, published today , is the largest study of its kind and pooled data from 18 previous studies and 20 countries including the UK and from across Western Europe, North America and Australia.
Online tool could help eliminate TB in countries with low transmission
A new online tool which could help eliminate tuberculosis in countries with low transmission rates such as the UK, by identifying who is at highest risk of developing TB, has been developed by UCL researchers. The research, published today , is the largest study of its kind and pooled data from 18 previous studies and 20 countries including the UK and from across Western Europe, North America and Australia.
A new online tool which could help eliminate tuberculosis in countries with low transmission rates such as the UK, by identifying who is at highest risk of developing TB, has been developed by UCL researchers. The research, published today , is the largest study of its kind and pooled data from 18 previous studies and 20 countries including the UK and from across Western Europe, North America and Australia.
Non-routine testing of patients with suspected Covid-19 ’of little benefit’ to assess risk
Non-routine testing of patients with suspected Covid-19 to help predict their prognosis on admission to emergency departments offers limited benefit and could have significant cost implications, according to a collaborative evaluation by Cardiff University and the University Hospital of Wales. Researchers drew together laboratory and clinical findings at Wales's largest hospital from the first wave of the pandemic using a newly created electronic healthcare resource, aimed at learning from routine care in the NHS.
Non-routine testing of patients with suspected Covid-19 to help predict their prognosis on admission to emergency departments offers limited benefit and could have significant cost implications, according to a collaborative evaluation by Cardiff University and the University Hospital of Wales. Researchers drew together laboratory and clinical findings at Wales's largest hospital from the first wave of the pandemic using a newly created electronic healthcare resource, aimed at learning from routine care in the NHS.
New Device for Detecting Traumatic Brain Injury ’On the Spot’
A method for detecting traumatic brain injury at the point of care has been developed by scientists at the University of Birmingham. Using chemical biomarkers released by the brain immediately after a head injury occurs, researchers are able to pinpoint when patients need urgent medical attention. This saves time in delivering vital treatment and avoids patients undergoing unnecessary tests where no injury has occurred.
A method for detecting traumatic brain injury at the point of care has been developed by scientists at the University of Birmingham. Using chemical biomarkers released by the brain immediately after a head injury occurs, researchers are able to pinpoint when patients need urgent medical attention. This saves time in delivering vital treatment and avoids patients undergoing unnecessary tests where no injury has occurred.
Scientists develop new ’Precision Medicine’ approach to treating damaged DNA in Pancreatic Cancer
Scientists have developed a new 'Precision Medicine' approach to treating the damaged DNA in the cancer cells of Pancreatic Cancer patients. The findings mark an important step forward for potential treatment options for pancreatic cancer, improving the options and outcomes for a disease where survival rates have remained stubbornly low.
Scientists have developed a new 'Precision Medicine' approach to treating the damaged DNA in the cancer cells of Pancreatic Cancer patients. The findings mark an important step forward for potential treatment options for pancreatic cancer, improving the options and outcomes for a disease where survival rates have remained stubbornly low.
